Literature DB >> 12504921

Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study.

Xavier Miró1, Silvia Pérez-Torres, Francesc Artigas, Pere Puigdomènech, José M Palacios, Guadalupe Mengod.   

Abstract

Changes in brain cyclic AMP (cAMP) have been suggested to underlie the clinical action of antidepressant treatments. Also, a regionally-selective regulation of cAMP-specific phosphodiesterases (PDEs) has been demonstrated for some antidepressants. To further investigate the effects of antidepressant treatments on PDEs, we examined the expression of different cAMP-specific PDEs in the brain of rats treated (1 and 14 days) with fluoxetine 3 mg/kg day. The mRNAs coding for PDE4A, PDE4B, PDE4D, and the five known PDE4D splice variants were analyzed by in situ hybridization on 45 brain structures of acute and chronic fluoxetine-treated rats. We also examined the binding sites for the putative antidepressant drug [(3)H]rolipram, a PDE4-selective inhibitor. In some brain areas single fluoxetine administration increased the density of the mRNA of all PDE4 isozymes, except PDE4D and PDE4D5. Chronic fluoxetine treatment increased PDE4A mRNA levels and decreased those for PDE4B, PDE4D and PDE4D1 mRNAs in some brain regions. The study was complemented with the analysis of the expression of the transcripts of BDNF. Chronic fluoxetine treatment down-regulated the expression of BDNF. These results show that the expression of PDE4 isozymes is modulated by a clinically relevant fluoxetine dose. The significance of these changes in PDE4 expression to the antidepressant effect of fluoxetine is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12504921     DOI: 10.1016/s0028-3908(02)00220-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  21 in total

1.  Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.

Authors:  Mary M Torregrossa; Emily M Jutkiewicz; Henry I Mosberg; Gianfranco Balboni; Stanley J Watson; James H Woods
Journal:  Brain Res       Date:  2005-12-20       Impact factor: 3.252

2.  Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model.

Authors:  Zacharias Kohl; Beate Winner; Kiren Ubhi; Edward Rockenstein; Michael Mante; Martina Münch; Carolee Barlow; Todd Carter; Eliezer Masliah; Jürgen Winkler
Journal:  Eur J Neurosci       Date:  2012-01       Impact factor: 3.386

3.  Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.

Authors:  Jacob P R Jacobsen; Adrianna Oh; Rachel Bangle; Wendy L Roberts; Elizabeth L Royer; Nathan Modesto; Sonora A Windermere; Zixuan Yi; Rebecca Vernon; Manuel Cajina; Nikhil M Urs; Joshua C Snyder; Peter J Nicholls; Benjamin D Sachs; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2019-04-29       Impact factor: 7.853

4.  Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: differential regulation of specific exons by antidepressants and corticosterone.

Authors:  Y Dwivedi; H S Rizavi; G N Pandey
Journal:  Neuroscience       Date:  2006-02-24       Impact factor: 3.590

Review 5.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

6.  Role of TrkB in the anxiolytic-like and antidepressant-like effects of vagal nerve stimulation: Comparison with desipramine.

Authors:  A P Shah; F R Carreno; H Wu; Y A Chung; A Frazer
Journal:  Neuroscience       Date:  2016-02-16       Impact factor: 3.590

7.  A Disc1 mutation differentially affects neurites and spines in hippocampal and cortical neurons.

Authors:  A M Lepagnol-Bestel; M Kvajo; M Karayiorgou; M Simonneau; J A Gogos
Journal:  Mol Cell Neurosci       Date:  2013-02-06       Impact factor: 4.314

8.  Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B).

Authors:  Han-Ting Zhang; Ying Huang; Anbrin Masood; Lisa R Stolinski; Yunfeng Li; Lei Zhang; Daniel Dlaboga; S-L Catherine Jin; Marco Conti; James M O'Donnell
Journal:  Neuropsychopharmacology       Date:  2007-08-15       Impact factor: 7.853

9.  Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment.

Authors:  S Alboni; R M van Dijk; S Poggini; G Milior; M Perrotta; T Drenth; N Brunello; D P Wolfer; C Limatola; I Amrein; F Cirulli; L Maggi; I Branchi
Journal:  Mol Psychiatry       Date:  2015-09-15       Impact factor: 15.992

10.  Brain-derived neurotrophic factor: role in depression and suicide.

Authors:  Yogesh Dwivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2009-08-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.